Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot study

Arthritis Care and Research

Volumn 53, Issue 3, 2005, Pages 337-342

  Matteson, Eric L ^a,f   Choi, Hyon K ^c   Poe, Dennis S ^d   Wise, Christopher ^e   Lowe, Val J ^a   McDonald, Thomas J ^a   Rahman, Mahboob U ^b,c  

^a Mayo Clinic   (United States)

^b Centocor ^*

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Etanercept; Hearing loss; Immune mediated cochleovestibular disease; Positron emission tomography

Indexed keywords

ANTIBIOTIC AGENT; CLONAZEPAM; CYCLOPHOSPHAMIDE; DIURETIC AGENT; ETANERCEPT; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LORAZEPAM; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; SEDATIVE AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; HEARING; HEARING LOSS; HUMAN; IMMUNE MEDIATED COCHLEOVESTIBULAR DISORDER; IMMUNOPATHOLOGY; INNER EAR; MALE; MENIERE DISEASE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; SCORING SYSTEM; SYMPTOM; TINNITUS; TREATMENT OUTCOME; VERTIGO; VESTIBULOCOCHLEAR NERVE DISEASE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOGLOBULIN G; LABYRINTH DISEASES; MALE; MENIERE'S DISEASE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 20444401580     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21179     Document Type: Article

References (29)

1. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585-9.
2. Toubi E, Ben-David J, Kessel A, Podoshin L, Golan TD. Autoimmune aberration in sudden sensorineural hearing loss: association with anti-cardiolipin antibodies. Lupus 1997;6:540-2.
3. Veldman JE, Roord JJ, O'Connor AF, Shea JJ. Autoimmunity and inner ear disorders: an immune-complex mediated sensorineural hearing loss. Laryngoscope 1984;94:501-7.
4. Summers RW, Harker L. Ulcerative colitis and sensorineural hearing loss: is there a relationship? J Clin Gastroenterol 1982;4:251-2.
5. Andonopoulos AP, Naxakis S, Goumas P, Lygatsikas C. Sensorineural hearing disorders in systemic lupus erythematosus: a controlled study. Clin Exp Rheumatol 1995;13:137-41.
6. Shea JJ. Autoimmune sensorineural hearing loss as an aggravating factor in Meniere's disease. Presented at the Barany Society Meeting; 1982 June; Basel, Switzerland: Barany Society; 1982.
7. Hughes GB, Kinney SE, Barna BP, Calabrese LH. Autoimmune reactivity in Meniere's disease: a preliminary report. Laryngoscope 1983;93:410-7.
8. Hughes GB, Kinney SE, Barna BP, Tomsak RL, Calabrese LH. Autoimmune reactivity in Cogan's syndrome: a preliminary report. Otolaryngol Head Neck Surg 1983;91:24-32.
9. Haynes BF, Pikus A, Kaiser-Kupfer M, Fauci AS. Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids. Arthritis Rheum 1981;24:501-3.
10. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-52.
11. Ryan AF, Keithley EM, Harris JP. Autoimmune inner ear disorders. Curr Opin Neurol 2001;14:35-40.
12. Rahman MU, Poe DS, Choi HK. Autoimmune vestibulo-cochlear disorders. Curr Opin Rheumatol 2001;13:184-9.
13. Matteson EL, Tirzaman O, Facer GW, Fabry DA, Kasperbauer J, Beatty CW, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-4.
14. Matteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CL, Strome SE, et al. Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Rheum 2001;45:146-50.
15. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003;290:1875-83.
16. Hoffman GS, Ken GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
17. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
18. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019-23.
19. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-8.
20. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
21. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
22. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
23. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:240, and N Engl J Med 2001;344:76]. N Engl J Med 2000;343:1586-93.
24. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 2001;22:619-24.
25. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope 1999;109:1749-54.
26. Mazlumzadeh M, Lowe VJ, Mullan BP, Fabry DA, McDonald TJ, Matteson EL. The utility of positron emission tomography in the evaluation of autoimmune hearing loss. Otol Neurotol 2003;24:201-4.
27. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18.
28. Raffin MJ, Thornton AR. Confidence levels for differences between speech-discrimination scores: a research note. J Speech Hear Res 1980;23:5-18.
29. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al, and the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.